In the case of SCD, in which a mutant form of HBB is the root cause of the disease, this approach combines the benefits of increased HbF levels with a reduction of the toxic form of HBB. These combinatorial effects might be beneficial when considering this strategy for the treatment of inherited diseases and enhanceropathies in cases where gene editing is not applicable. This evidence concerns the gene HBB and Schnyder corneal dystrophy.